Metformin for the treatment of unruptured vertebrobasilar dissecting aneurysm (METTLE): study protocol for a double-blinded randomised controlled trial
Abstract
Background: Vertebrobasilar dissecting aneurysm (VBDA) has high morbidity and mortality rates, and it is an important cause of stroke in young and middle-aged adults. Previous studies have shown that aneurysm wall inflammation is a major factor contributing to the high risk of aneurysm growth and rupture. Metformin inhibits inflammation and may be a suitable candidate drug for VBDA. Here, we report the protocol for a study designed to evaluate the ability of metformin to reduce the degree of aneurysm wall inflammation in patients with VBDA, as measured by high-resolution vessel wall imaging (HR-VWI).
Methods: The study is a multicentre, prospective, randomised, controlled, and blinded clinical trial. Sixty patients with unruptured VBDA who meet the inclusion/exclusion criteria will be recruited competitively from three hospitals in China. Patient recruitment began in May 2024 and is expected to end in December 2025. The patients will be randomised (1:1) to treatment or placebo (n = 30 in each group), receiving either 250-mg metformin or placebo orally twice per day for 6 months. The primary outcome will be the change in VBDA wall inflammation measured by HR-VWI. The secondary outcomes will be changes in VBDA morphology, typical imaging signs, and inflammatory biomarkers.
Discussion: Previous studies on metformin for the treatment of intracranial aneurysms have been performed in animals. However, prospective clinical studies in humans are lacking. Therefore, this study will…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 30 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.